NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Journal Article


Authors: Wierda, W. G.; Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Caimi, P.; Fayad, L. E.; Fisher, R. I.; Glenn, M. J.; Habermann, T. M.; Harris, N. L.; Hernandez-Ilizaliturri, F.; Hoppe, R. T.; Horwitz, S. M.; Kaminski, M. S.; Kelsey, C. R.; Kim, Y. H.; Krivacic, S.; LaCasce, A. S.; Martin, M. G.; Nademanee, A.; Porcu, P.; Press, O.; Rabinovitch, R.; Reddy, N.; Reid, E.; Roberts, K.; Saad, A. A.; Snyder, E. D.; Sokol, L.; Swinnen, L. J.; Vose, J. M.; Yahalom, J.; Dwyer, M. A.; Sundar, H.
Article Title: NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
Abstract: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL. © 2017 National Comprehensive Cancer Network, Inc. All rights reserved.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 15
Issue: 3
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2017-03-01
Start Page: 293
End Page: 311
Language: English
PROVIDER: scopus
PUBMED: 28275031
DOI: 10.6004/jnccn.2017.0030
DOI/URL:
Notes: Review -- Export Date: 2 May 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    625 Yahalom
  2. Steven M Horwitz
    645 Horwitz
  3. Andrew D Zelenetz
    767 Zelenetz